Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT02904902 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02904902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02904902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
September 6, 2016
Completion date
May 30, 2019
Enrollment
15 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa